Logo image of KNE.CA

KANE BIOTECH INC (KNE.CA) Stock Fundamental Analysis

TSX-V:KNE - TSX Venture Exchange - CA4838092084 - Common Stock - Currency: CAD

0.05  0 (0%)

Fundamental Rating

2

Overall KNE gets a fundamental rating of 2 out of 10. We evaluated KNE against 23 industry peers in the Biotechnology industry. KNE has a bad profitability rating. Also its financial health evaluation is rather negative. KNE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year KNE was profitable.
In the past year KNE has reported a negative cash flow from operations.
In the past 5 years KNE reported 4 times negative net income.
KNE had a negative operating cash flow in each of the past 5 years.
KNE.CA Yearly Net Income VS EBIT VS OCF VS FCFKNE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

1.2 Ratios

Looking at the Return On Assets, with a value of 225.92%, KNE belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 225.92%
ROE N/A
ROIC N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNE.CA Yearly ROA, ROE, ROICKNE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K 40K 50K

1.3 Margins

KNE has a Profit Margin of 255.02%. This is amongst the best in the industry. KNE outperforms 100.00% of its industry peers.
KNE has a better Gross Margin (35.82%) than 69.57% of its industry peers.
KNE's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 255.02%
GM 35.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
KNE.CA Yearly Profit, Operating, Gross MarginsKNE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

KNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KNE has been increased compared to 1 year ago.
KNE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for KNE has been reduced compared to a year ago.
KNE.CA Yearly Shares OutstandingKNE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KNE.CA Yearly Total Debt VS Total AssetsKNE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

KNE has an Altman-Z score of -21.03. This is a bad value and indicates that KNE is not financially healthy and even has some risk of bankruptcy.
KNE's Altman-Z score of -21.03 is in line compared to the rest of the industry. KNE outperforms 52.17% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.03
ROIC/WACCN/A
WACC11.58%
KNE.CA Yearly LT Debt VS Equity VS FCFKNE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

KNE has a Current Ratio of 0.56. This is a bad value and indicates that KNE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.56, KNE perfoms like the industry average, outperforming 43.48% of the companies in the same industry.
A Quick Ratio of 0.49 indicates that KNE may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.49, KNE is in line with its industry, outperforming 43.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.49
KNE.CA Yearly Current Assets VS Current LiabilitesKNE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 174.50% over the past year.
Looking at the last year, KNE shows a very strong growth in Revenue. The Revenue has grown by 54.91%.
The Revenue has been growing slightly by 4.21% on average over the past years.
EPS 1Y (TTM)174.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.32%
Revenue 1Y (TTM)54.91%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%694.8%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNE.CA Yearly Revenue VS EstimatesKNE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 1.00 indicates a rather cheap valuation of KNE.
Based on the Price/Earnings ratio, KNE is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
KNE is valuated cheaply when we compare the Price/Earnings ratio to 27.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 1
Fwd PE N/A
KNE.CA Price Earnings VS Forward Price EarningsKNE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNE.CA Per share dataKNE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KNE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KANE BIOTECH INC

TSX-V:KNE (7/4/2025, 7:00:00 PM)

0.05

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-22 2025-05-22
Earnings (Next)08-27 2025-08-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners39.86%
Ins Owner ChangeN/A
Market Cap8.29M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1
Fwd PE N/A
P/S 3.39
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.05
EY100%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 225.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 255.02%
GM 35.82%
FCFM N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.15%
Cap/Sales 5.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.49
Altman-Z -21.03
F-Score4
WACC11.58%
ROIC/WACCN/A
Cap/Depr(3y)31.77%
Cap/Depr(5y)88.96%
Cap/Sales(3y)13.66%
Cap/Sales(5y)14.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)54.91%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%694.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.11%
OCF growth 3YN/A
OCF growth 5YN/A